| PROTAGEN Aktiengesellschaft Patent applications |
| Patent application number | Title | Published |
|---|
| 20110275528 | MARKER SEQUENCES FOR INFLAMMATORY PROSTATE DISEASES, PROSTATE CARCINOMA AND THEIR USE - The present invention relates to novel marker sequences for inflammatory prostate diseases, prostate carcinoma and the diagnostic use thereof together with a method for screening of potential active substances for inflammatory prostate diseases, prostate carcinoma by means of these marker sequences. Furthermore, the invention relates to a diagnostic device containing such marker sequences for inflammatory prostate diseases, prostate carcinoma, in particular a protein biochip and the use thereof. | 11-10-2011 |
| 20110184375 | MARKER SEQUENCE FOR NEURODEGENERATIVE DISEASES AND THE USE THEREOF - The present invention relates to new marker sequences for neurodegenerative diseases and the diagnostic use thereof together with a method for screening of potential active substances for neurodegenerative diseases by means of these marker sequences. Furthermore, the invention relates to a diagnostic device containing such marker sequences for neurodegenerative diseases, in particular a protein biochip and the use thereof. | 07-28-2011 |
| 20100331201 | PROTEIN BIOCHIP FOR THE DIFFERENTIAL SCREENING OF PROTEIN-PROTEIN INTERACTIONS - The present invention relates to a system of protein binders containing at least one protein binder presented in at least one native form and at least one non-native form and its use including a method for discrimination and/or differential screening of suitable protein binders in native and non-native form. | 12-30-2010 |
| 20100062059 | S-Nitrosothiols Containing Composition for the Treatment of Fatty Liver Diseases, Obesity and Other Diseases Associated with the Metabolic Syndrome and the Use of Such Compositions - The present invention refers to pharmaceutical compositions containing S-nitrosothiols as active principle. The referred compositions are intended for the treatment of the fatty liver disease and other diseases associated with the metabolic syndrome. The composition is administered either orally or rectally. | 03-11-2010 |
